pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ivonescimab · news · pharmadog
← back to ivonescimab
News mentioning ivonescimab
49
stories
6d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
7d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
7d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
7d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
7d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
14d
Compass vows to press on with FDA application despite new trial request
biospace
18d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
21d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
22d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
22d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
endpoints
Aug 27, 26
Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal
endpoints
Aug 27, 26
What’s in Merck and Moderna’s cancer vaccine algorithm?
stat
Aug 26, 26
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
biopharma dive
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
endpoints
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 20, 26
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
Aug 19, 26
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
Aug 17, 26
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
Aug 17, 26
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
Aug 13, 26
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China
raps
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
← prev
page 1 of 2
next →
